Inflammation causes colorectal cancer because of the loss of this protein

Share This Post

Chronic inflammation is a  predisposing factor for colorectal cancer, which is the third leading cause of cancer-related deaths in the United States. Dr. Anna Means and colleagues reported in the journal Cell and Molecular Gastroenterology and Hepatology last month that they linked the inflammation-driven  carcinogenesis of the colon to the loss of an important signaling protein called SMAD4. SMAD4 is part of the transforming growth factor β (TGF-β) signaling pathway, which regulates the immune and inflammatory response to infection in the colonic epithelium.

The specific deletion of SMAD4 gene in normal mouse colon epithelial cells grown in vivo increased the expression of inflammatory  mediators. In adult mice with inflammation, the lack of SMAD4 results in a surprising similarity between tumors and cancers associated with human colitis.

Loss of SMAD4 was also observed in 48% of human colitis-related cancers, compared with 19% of scattered colorectal cancers. “This loss may be an important factor from premalignant lesions to aggressive malignant tumors,” the researchers concluded. Therefore, friends with chronic inflammation must eliminate inflammation in time, and do not regret it until the inflammation develops into cancer.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy